|Day's range||0.057 - 0.068|
|52-week range||0.015 - 0.085|
|PE ratio (TTM)||-2.72|
|Earnings date||31 Mar. 2017 - 1 Apr. 2017|
|Dividend & yield||N/A (N/A)|
|1y target est||0.01|
BOSTON & SYDNEY--(BUSINESSWIRE)-- GI Dynamics® Inc. (ASX:GID.AX - News), a medical device company that has commercialized EndoBarrier® in Europe, the Middle East and South America for patients with type 2 diabetes and obesity announced additional members of the GI Dynamics Scientific Advisory Board (SAB), bringing together distinguished physicians and scientists specializing in endocrinology, gastroenterology and bariatric/metabolic surgery. Francesco Rubino, MD, and Philip Schauer, MD have joined the GI Dynamics SAB. The GI Dynamics SAB was designed to advance the body of evidence and state of patient care through EndoBarrier utilization.
GI Dynamics conducted the financing solely with its major shareholder, Crystal Amber Fund Limited. The financing is intended to provide GI Dynamics with adequate working capital through the remainder of 2017. In connection with the financing, GI Dynamics has been granted a waiver from ASX Listing Rule 10.1 to facilitate the security arrangements.
BOSTON & SYDNEY--(BUSINESSWIRE)-- GI Dynamics ® , Inc., (ASX:GID), a medical device company that has commercialized EndoBarrier ® in Europe for patients with type 2 diabetes and obesity, today announced ...